

## Transparency Information

**Leuven (BELGIUM) – December 3, 2015** – TiGenix NV (Euronext Brussels: TIG) publishes information in accordance with articles 15 and 18 of the Belgian Law of May 2, 2007 regarding the publication of major holdings in issuers whose securities are admitted to trading on a regulated market and including various provisions (the Law) and the Royal Decree of February 14, 2008 regarding the publication of major holdings.

Following the closing of the second tranche of the private placement announced on November 25, 2015, resulting in the issuance of 4,956,894 new shares, the transparency data have changed as follows (status on December 3, 2015):

- **Information to be published in accordance with Article 15, §1, al. 1 of the Law**

Total of the registered capital:	EUR 17,729,555.70
Total number of securities conferring voting rights:	177,295,557
Total number of voting rights (denominator):	177,295,557

- **Information to be published in accordance with Article 15, §1, al. 2 of the Law**

Total number of rights (materialized or not in financial instruments) to subscribe to yet unissued financial instruments that are treated as securities conferring voting rights: 8,581,200 outstanding warrants which, in case they are all exercised, give rise to a total number of 8,581,200 voting rights.

Total number of bonds convertible into securities conferring voting rights: 250 bonds which, in case they are all converted at the initial conversion price, give rise to a total number of 26,556,192 voting rights.

TiGenix NV has not issued any other rights to subscribe to securities conferring voting rights or any securities without voting rights.

- **Information to be published in accordance with Article 18, §1 of the Law**

Each physical or legal person acquiring or transferring TiGenix' shares is required to notify the Belgian Financial Services and Markets Authority (FSMA) and TiGenix NV each time their shareholding crosses a threshold of three percent (3%) of the total number of voting securities (the denominator) (upwards or downwards). Such notification is also required when the threshold of five percent (5%) or a multiple of five percent (5%) is crossed.

Complete information regarding this requirement can be found in Article 14 of the articles of association of TiGenix NV.

Notifications must be submitted to both the FSMA and TiGenix NV.

# TIGENIX

To the FSMA:

- by e-mail: [trp.fin@fsma.be](mailto:trp.fin@fsma.be), and
- a signed copy (for reasons of legal certainty) by fax: +32 2 220 59 12

A copy of the notification must also be sent to TiGenix NV for the attention of Claudia D'Augusta, CFO:

- by e-mail: [investor@tigenix.com](mailto:investor@tigenix.com), and
- a signed copy (for reasons of legal certainty) by fax: +32 16 39 79 70

For submitting the notifications, the FSMA recommends to use its standard form TR-1BE that is available on the FSMA website (<http://www.fsma.be/en/supervision/fm/gv/ah/circah/ov.aspx>) or can be requested by e-mail with TiGenix NV: [investor@tigenix.com](mailto:investor@tigenix.com).

Detailed information regarding the transparency legislation can be found on the website of the FSMA.

## For more information

Claudia D'Augusta  
Chief Financial Officer  
T: +34 91 804 92 64  
[claudia.daugusta@tigenix.com](mailto:claudia.daugusta@tigenix.com)

## About TiGenix

*TiGenix NV (Euronext Brussels: TIG) is an advanced biopharmaceutical company focused on developing and commercialising novel therapeutics from its proprietary platforms of allogeneic, or donor-derived, expanded stem cells. Two products from the adipose-derived stem cell technology platform are currently in clinical development. Cx601 is in Phase III for the treatment of complex perianal fistulas in Crohn's disease patients. Cx611 has completed a Phase I sepsis challenge trial and a Phase I/II trial in rheumatoid arthritis. Effective July 31, 2015, TiGenix acquired Coretherapix, whose lead cellular product, AlloCSC-01, is currently in a Phase II clinical trial in acute myocardial infarction (AMI). In addition, the second product candidate from the cardiac stem cell-based platform acquired from Coretherapix, AlloCSC-02, is being developed in a chronic indication. TiGenix also developed ChondroCelect, an autologous cell therapy product for cartilage repair of the knee, which was the first Advanced Therapy Medicinal Product (ATMP) to be approved by the European Medicines Agency (EMA). From June 2014, the marketing and distribution rights of ChondroCelect were exclusively licensed to Sobi for the European Union (except for Finland, where it is distributed by the Finnish Red Cross Blood Service), Norway, Russia, Switzerland and Turkey, and the countries of the Middle East and North Africa. TiGenix is headquartered in Leuven (Belgium) and has operations in Madrid (Spain).*